[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Australia Update", "description": "Life is essentially back to normal in Australia, Mr. David Davies reports from Australia\n\nAgUnity main link\nhttps://www.agunity.com\n\nAgUnity is an Australian tech-for-good start-up empowering thousands of organizations working towards the UN Sustainable Development Goals to better connect with the last mile. By enabling trust, increasing transparency, giving access to market and limiting corruption through blockchain technology, AgUnity provides smallholder farmers a platform that is relevant and useful for them, essentially empowering them to lift themselves out of poverty. For more info, visit www.agunity.com or contact them via hello@agunity.com.", "link": "https://www.youtube.com/watch?v=L5DojKdL5dw", "date_published": "2020-11-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Australia and the world", "description": "Mr David Davies highlights some essential principles for a sustainable future, illustrated through his AgUnity work.\n\nAgUnity is an Australian tech-for-good start-up empowering thousands of organizations working towards the UN Sustainable Development Goals to better connect with the last mile. By enabling trust, increasing transparency, giving access to market and limiting corruption through blockchain technology, AgUnity provides smallholder farmers a platform that is relevant and useful for them, essentially empowering them to lift themselves out of poverty. For more info, visit www.agunity.com or contact them via hello@agunity.com.\n\nAgUnity resources, https://agunity.sharepoint.com/sites/agunityexternalshare/Shared%20Documents/Forms/AllItems.aspx?id=%2Fsites%2Fagunityexternalshare%2FShared%20Documents%2F00%20AgUnity%20Media%20for%20External%20Parties%2F01%20Field%20Footage%20for%20Dr%20Campbell&p=true&originalPath=aHR0cHM6Ly9hZ3VuaXR5LnNoYXJlcG9pbnQuY29tLzpmOi9zL2FndW5pdHlleHRlcm5hbHNoYXJlL0VxVzlxMkRkT2ZaSmdBUVZEUDF0UUg0QnVvWlNJS0JFVU1hcnZZOF85VkVkcHc_cnRpbWU9TVJNeng2T1EyRWc", "link": "https://www.youtube.com/watch?v=eVTPtM6LzqU", "date_published": "2020-11-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Oxford vaccine, looking very good", "description": "US Influenza\nOxford / AstraZeneca \n\nPhase 2 / 3\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext\n\n\n(23rd November)\n\nhttps://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html\n\nViral vector, weakened version, chimpanzee, common cold adenovirus\n\nAfter vaccination, the surface spike protein is produced\n\nAntibodies\n\nT cells\nInterim report, 131 confirmed infections\nPositive high-level results\n8,000 swabs per week\nTherefore picking up asymptomatics\nClinical trials of AZD1222\nUK and Brazil data only\nVaccine was highly effective in preventing COVID-19\nNo hospitalisations or severe cases of the disease were reported in participants receiving the vaccine\nGroup one, n = 2,741\nAZD1222 was given as a half dose\nFollowed by a full dose\nAt least one month apart\nVaccine efficacy of 90%\nGroup 2, n = 8,895\nTwo full doses at least one month apart\nVaccine efficacy 62 %\nCombined analysis from both dosing regimens, n = 11,636\nAn average efficacy of 70%\nAll results were statistically significant (p less than  = 0.0001)\nOne in 10,000\nMore data will continue to accumulate\nRefining the efficacy reading \nEstablishing the duration of protection.\nIndependent Data Safety Monitoring Board\nMet its primary endpoint\nProtection from COVID-19 occurring 14 days or more after receiving two doses\nNo serious safety events related to the vaccine have been confirmed\nAZD1222 was well tolerated across both dosing regimens\nAstraZeneca immediately prepare regulatory submission\nEarly approval\nEmergency Use Listing from the World Health Organization\nFor an accelerated pathway to low-income countries\nFull analysis of the interim results is being submitted for peer-reviewed journal\nProfessor Andrew Pollard\nThese  findings  show  that  we  have  an  effective  vaccine  that  will  save  many  lives\nExcitingly, we\u2019ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, \nmore people could be vaccinated with planned vaccine supply\nPascal Soriot, Chief Executive Officer\nSimple supply chain\nno-profit pledge\ncommitment to broad, equitable and timely access means\nit will be affordable and globally available\nsupplying hundreds of millions of doses on approval\nControl group\nMeningococcal conjugate vaccine called MenACWY\nor saline\nParticipants \nAged 18 years or over\nDiverse racial and geographic groups\nHealthy or have stable underlying medical conditions\nClinical trials are also being conducted in\nUS, Japan, Russia, South Africa, Kenya, Latin America\nPlanned trials in other European and Asian countries\nN = 60,000\nManufacturing capacity\n3 billion doses in 2021\nStorage / transport\n2-8 degrees Celsius\n36-46 degrees Fahrenheit\nFor at least six months\nAdministered within existing healthcare settings\nCOV002\nA single-blinded, multi-centre, randomised, controlled Phase II/III trial\nAssessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK\nAged 18 years or over\nHealthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus\nGroup one\nOne or two intramuscular doses of a half dose (~2.5 x1010 viral particles)\nComparator, meningococcal vaccine MenACWY.\nGroup two \nFull dose (~5x1010 viral particles)\nComparator, meningococcal vaccine MenACWY.\nClinical assessments for safety as well as immunogenicity\nMultiple timepoints\nFor a year\nWeekly swabbing for viral presence\nCOV003\nCOV003 is a single-blinded, multi-centre, randomised, controlled Phase III trial in Brazil\nTwo intramuscular doses of a full dose (~5x1010 viral particles) of AZD1222 or comparator\nMeningococcal vaccine MenACWY as first dose and a saline placebo as second dose\nUK, Oxford / Astrazeneca \nThe UK has ordered 100m doses\nUS also\nUK government has supplied \u00a365.5m towards the development\nContracts with France, Germany, Italy and the Netherlands, up to 400 million doses\nSerum Institute of India, vaccine alliances, production for poorer countries, 1 billion doses\nChina, Brazil, Japan and Russia have also expressed interest.", "link": "https://www.youtube.com/watch?v=wAvnAkAMmmM", "date_published": "2020-11-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "DW News Interview", "description": "Thanks as always to DW news", "link": "https://www.youtube.com/watch?v=1_3bRvsjvy0", "date_published": "2020-11-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Second Vitamin D clinical trial, positive results", "description": "Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)\n\nhttps://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065.full\n\n\nIt has been observed that vitamin D-deficient individuals \nhave increased COVID-19 risk and mortality\n\nPharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020;323:1824\u201336. doi: 10.1001/jama.2020.6019\n\nThe role of vitamin D in the prevention of coronavirus disease infection and mortality. \n\nAging Clin Exp Res 2020;32:1195\u20138. doi: 10.1007/s40520-020-01570-8 \n\nAssociation of vitamin D status and other clinical characteristics with COVID-19 test results. \n\nJAMA Netw Open 2020;3:e2019722. (Published 3 Sep 2020).doi: 10.1001/jamanetworkopen.2020.19722 \n\nImmunomodulatory role and protective effect of vitamin D against other viral infections\n\nVitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;15:356:i6583. doi: 10.1136/bmj.i6583 \n\nAn intervention study with calcifediol noticed a reduction in requirement for intensive care among hospitalised patients for COVID19\n\nEffect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study.\n\nJ Steroid Biochem Mol Biol 2020;203:105751. doi: 10.1016/j.jsbmb.2020.105751\n \n50 patients treated with calcifediol, one required admission to the ICU (2%), no deaths\n\n26 untreated patients, 13 required admission (50 %) to the ICU, 2 deaths\n\nImmune-modulatory effect of vitamin D is likely to be observed at 25(OH)D levels, which are considered higher than that required for its skeletal effects\n\nVitamin D to prevent COVID-19: recommendations for the design of clinical trials. Febs J2020;287:3689\u201392. doi: 10.1111/febs.15534 \n\nPositive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults.\n\nBMC Res Notes 2012;5:575. doi: 10.1186/1756-0500-5-575\n\nVitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection.\n\n PLoS One 2020;15:e0239799.doi: 10.1371/journal.pone.0239799 \n\nAim\n\nhttps://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065.full\n\nEffect of high dose, oral cholecalciferol supplementation on SARS-CoV-2 viral clearance\n\nFirst cholecalciferol intervention study for asymptomatic and mildly symptomatic SARS-CoV-2 positive individuals\n\n\nDesign\n\nRandomised, placebo-controlled.\n\nParticipants\n\nAsymptomatic or mildly symptomatic SARS-CoV-2 \n\nRNA positive vitamin D deficient (25(OH) D less than 20 ng/ml)\n\nCalcifediol, calcidiol, 25-hydroxycholecalciferol, or 25-hydroxyvitamin D3\n\nPre intervention baseline serum 25(OH) D\n\nIntervention group, 8.6 ng/ml\n\nControl group, 9.54 ng/ml (p=0.730)\n\n10 out of 16 patients could achieve 25(OH)D more than 50 ng/ml by \nday-7\n\nAnother two by day-14\n\nOutcome measure\n\nProportion of patients with SARS-CoV-2 RNA negative before day-21\n\nChange in inflammatory markers\n\nIntervention group (n=16)\n\n60 000 IU of cholecalciferol (oral nano-liquid droplets) for 7 days\n\nTherapeutic target 25(OH)D more than 50 ng/ml\n\nCholecalciferol supplementation was continued for those with 25(OH)D less than 50 ng/ml\n\nFibrinogen levels significantly decreased with cholecalciferol supplementation \n\n10 (62.5%) participants became SARS-CoV-2 RNA negative\n\nControl group (n=24)\n\nPlacebo\n\n5 (20.8%) participants became SARS-CoV-2 RNA negative (p less than 0.018)\n\nBoth groups\n\nPatients requiring invasive ventilation or with significant comorbidities were excluded\n\n25(OH)D levels were assessed at day 7\n\nRegular measurements of: SARS-CoV-2 RNA, fibrinogen, D-dimer, procalcitonin, CRP, ferritin\n\nImprovements\n\nCalcifediol would have been better\n\nLittle and often for prevention", "link": "https://www.youtube.com/watch?v=7H2c0Zm6PFw", "date_published": "2020-11-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]